{"id":"NCT01188564","sponsor":"Pharming Technologies B.V.","briefTitle":"Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks","officialTitle":"A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-01","primaryCompletion":"2012-12","completion":"2013-03","firstPosted":"2010-08-25","resultsPosted":"2015-08-07","lastUpdate":"2015-08-07"},"enrollment":75,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hereditary Angioedema"],"interventions":[{"type":"DRUG","name":"rhC1INH","otherNames":[]},{"type":"DRUG","name":"Placebo (Saline)","otherNames":[]}],"arms":[{"label":"rhC1INH","type":"EXPERIMENTAL"},{"label":"Placebo (Saline)","type":"PLACEBO_COMPARATOR"}],"summary":"This study is being conducted to confirm the efficacy, safety, and immunogenicity of recombinant human C1 inhibitor (rhC1INH) at a dose of 50 U/kg when used for the treatment of acute angioedema attacks in Hereditary Angioedema (HAE) patients.","primaryOutcome":{"measure":"Time to Beginning of Relief of Symptoms","timeFrame":"Patients observed for 24 hours","effectByArm":[{"arm":"rhC1INH","deltaMin":90,"sd":null},{"arm":"Placebo (Saline)","deltaMin":152,"sd":null}],"pValues":[]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":27,"countries":["United States","Bulgaria","Canada","Hungary","Israel","Italy","North Macedonia","Poland","Romania","Serbia","South Africa"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":56},"commonTop":["Sinus congestion","Sneezing","Vasomotor rhinitis","Diarrhea","Dyspepsia"]}}